普通人群中CFTR Phe508del突变携带者的疾病与死亡风险
在108 034名丹麦白人中,3%为CFTR Phe508del携带者,其总体生存与非携带者相似,但慢性支气管炎、支气管扩张和肺癌风险升高。
要点
- CFTR Phe508del携带者总体生存与非携带者相似。
- 携带者慢性支气管炎风险为非携带者的1.31倍(95%CI 1.16-1.48)。
- 携带者支气管扩张和肺癌风险分别升高至1.88倍和1.52倍。
核心结论
- 普通人群中CFTR Phe508del携带者寿命正常,但慢性支气管炎、支气管扩张和肺癌风险增加。
研究设计与样本
- 研究纳入Copenhagen General Population Study中108 035名随机选择的20-100岁丹麦白人,进行CFTR Phe508del(rs113993960)基因分型。
- 排除1名纯合子已知CF患者后,最终分析108 034人,其中2858名(3%)为携带者(杂合子),105 176名(97%)为非携带者。
- 慢性支气管炎和气流受限为横断面评估;总生存及支气管扩张、肺癌、肺炎等结局前瞻性随访至15年(中位9年)。
主要发现
- 携带者与非携带者总体生存相似。
- 多变量调整后,携带者慢性支气管炎OR为1.31(95%CI 1.16-1.48)。
- 携带者支气管扩张HR为1.88(95%CI 1.03-3.45),肺癌HR为1.52(95%CI 1.12-2.08)。
- 携带者与非携带者在肺功能及其他上述疾病结局方面无差异。
临床怎么用
- 对CFTR Phe508del携带者应关注慢性支气管炎、支气管扩张和肺癌的筛查与早期识别。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Cystic fibrosis (CF) is caused by autosomal-recessive inheritance of a dysfunctional cystic fibrosis transmembrane conductance regulator (CFTR), up to 90% due to Phe508del mutation in the CFTR gene. We tested the hypothesis that CFTR Phe508del carriers have increased morbidity and mortality versus non-carriers in the general population.We genotyped 108 035 randomly selected white Danish individuals from the Copenhagen General Population Study (aged from 20-100 years) for CFTR Phe508del mutation (rs113993960). Risk of chronic bronchitis and airflow limitation was assessed cross-sectionally. Overall survival and risk of bronchiectasis, lung cancer, pneumonia, chronic rhinosinusitis, airway bleeding, spontaneous pneumothorax, respiratory failure, acute and chronic pancreatitis, liver cirrhosis, ileus, gastric and colorectal cancer, and male infertility were assessed prospectively during up to 15 years of follow-up (median: 9 years). A single individual was excluded due to homozygosity for CFTR Phe508del and known CF. No other individuals had diagnosed CF at baseline examination or during follow-up.Among the resulting 108 034 individuals, 105 176 (97%) were non-carriers and 2858 (3%) were carriers (i.e. were heterozygous for CFTR Phe508del). Overall survival was similar between carriers and non-carriers. Compared to non-carriers and with multivariable adjustment, carriers had an odds ratio (OR) of 1.31 (95% CI 1.16-1.48) for chronic bronchitis, a hazard ratio (HR) of 1.88 (95% CI 1.03-3.45) for bronchiectasis and 1.52 (95% CI 1.12-2.08) for lung cancer. Carriers did not differ from non-carriers concerning lung function or any other morbidity outcomes as mentioned above.In the general population, carriers of CFTR Phe508del have a normal lifespan but an increased risk of chronic bronchitis (1.3-fold), bronchiectasis (1.9-fold) and lung cancer (1.5-fold).
引用
- Çolak Y, Nordestgaard BG, Afzal S, et al. Morbidity and mortality in carriers of the cystic fibrosis mutation CFTR Phe508del in the general population. Eur Respir J. 2020. PMID: 32398304. doi:10.1183/13993003.00558-2020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。